| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Athenex Inc (NASDAQ: ATNX)
ATNX Technical Analysis
5
| As on 9th Jun 2023 ATNX STOCK Price closed @ 0.14 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.65 & Strong Sell for SHORT-TERM with Stoploss of 1.10 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ATNXSTOCK Price
| Open | 0.14 | Change | Price | % |
| High | 0.18 | 1 Day | 0.00 | 0.00 |
| Low | 0.11 | 1 Week | -0.06 | -30.00 |
| Close | 0.14 | 1 Month | -1.02 | -87.93 |
| Volume | 66639 | 1 Year | -1.43 | -91.08 |
| 52 Week High 4.38 | 52 Week Low 0.10 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ATNX Daily Charts |
ATNX Intraday Charts |
Whats New @ Bazaartrend |
ATNX Free Analysis |
|
|
ATNX Important Levels Intraday
| RESISTANCE | 0.27 |
| RESISTANCE | 0.23 |
| RESISTANCE | 0.20 |
| RESISTANCE | 0.18 |
| SUPPORT | 0.10 |
| SUPPORT | 0.08 |
| SUPPORT | 0.05 |
| SUPPORT | 0.01 |
ATNX Forecast May 2024
| 4th UP Forecast | 1.49 |
| 3rd UP Forecast | 1.06 |
| 2nd UP Forecast | 0.79 |
| 1st UP Forecast | 0.52 |
| 1st DOWN Forecast | -0.24 |
| 2nd DOWN Forecast | -0.51 |
| 3rd DOWN Forecast | -0.78 |
| 4th DOWN Forecast | -1.21 |
ATNX Weekly Forecast
| 4th UP Forecast | 0.51 |
| 3rd UP Forecast | 0.39 |
| 2nd UP Forecast | 0.32 |
| 1st UP Forecast | 0.24 |
| 1st DOWN Forecast | 0.04 |
| 2nd DOWN Forecast | -0.04 |
| 3rd DOWN Forecast | -0.11 |
| 4th DOWN Forecast | -0.23 |
ATNX Forecast2024
| 4th UP Forecast | 8.85 |
| 3rd UP Forecast | 6.06 |
| 2nd UP Forecast | 4.33 |
| 1st UP Forecast | 2.6 |
| 1st DOWN Forecast | -2.32 |
| 2nd DOWN Forecast | -4.05 |
| 3rd DOWN Forecast | -5.78 |
| 4th DOWN Forecast | -8.57 |
Athenex Inc ( NASDAQ USA Symbol : ATNX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ATNX Business Profile
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. Address: Conventus Building, Buffalo, NY, United States, 14203
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service